How to Import Pharmaceutical Products from India to Europe
India is one of the world’s largest exporters of pharmaceutical products — supplying a significant share of global generic medicines and active pharmaceutical ingredients (APIs) to markets across Europe, North America, and beyond. For European distributors, the appeal is straightforward: cost-competitive manufacturing, high production volumes, and established export infrastructure. The compliance path, however, is anything but straightforward. Importing pharmaceutical products from India to Europe requires a structured series of regulatory steps — Manufacturing Import Authorisation, Qualified Person certification, EU GMP compliance, and verified marketing authorisation — that cannot be shortcut or resequenced. This guide explains each requirement clearly, in the order it applies.
Quick Answer
To import pharmaceutical products from India to Europe, your EU-based import operation must hold a Manufacturing and Import Authorisation (MIA) issued by your national competent authority. Every batch imported from India must be re-tested and certified by a Qualified Person (QP) before release. The Indian manufacturing site must comply with EU GMP — verifiable through the EudraGMDP public database. The product must have a valid EU marketing authorisation before it can be sold or supplied on the EU market.
Why the EU Treats Pharmaceutical Importers as Manufacturers
The EU regulatory framework makes a deliberate and consequential decision: it classifies pharmaceutical importers as manufacturers. This is not a technicality. It means that any organisation importing medicinal products into the European Economic Area (EEA) from a third country — including India — is subject to the same regulatory obligations as a manufacturer operating inside the EU.
The practical consequence is that you cannot simply arrange a purchase agreement with an Indian pharmaceutical manufacturer and begin importing. Manufacturers and importers located in the European Economic Area must hold an authorisation issued by the national competent authority of the member state where they carry out these activities. That authorisation is the Manufacturing and Import Authorisation — the MIA. Without it, you cannot legally import medicinal products into the EU, regardless of how reputable the Indian manufacturer is.
What the MIA Requires
Importers are required to adhere to GMP standards as MIA holders. This includes establishing a pharmaceutical quality system, having sufficient personnel and workspace for the relevant activities, planning appropriately for the handling of complaints and recalls, and implementing protocols to manage their supply chains. The MIA is issued by the national competent authority of the EU member state where your import operation is based — in Germany that is the regional authority, in France it is the ANSM, in the Netherlands the MEB, and so on.
The MIA application requires you to demonstrate that your import facility, your quality systems, and your personnel meet EU GMP standards before authorisation is granted. It is not a registration or a notification — it is an authorisation that follows inspection. Plan for a process that takes months, not weeks.
For organisations that do not wish to obtain their own MIA, it is possible to contract with an established EU MIA holder who provides QP services and batch release under their own authorisation. This is a common route for smaller distributors entering the EU market, but it requires a formal written agreement between all parties — the Indian manufacturer, the EU importer, the QP certification site, and the marketing authorisation holder — clearly defining each party’s responsibilities.
The Qualified Person — The Central Compliance Requirement
The Qualified Person is the individual legally responsible for certifying each batch of imported medicinal product before it is released onto the EU market. No batch can be released without QP certification. This is not optional and cannot be delegated to a non-QP.
All medicinal products imported into the European Economic Area from third countries must be re-tested for compliance with the EU marketing authorisation and certified by a Qualified Person. Only then can these products be released onto the EU market. The QP’s certification is a formal declaration — backed by evidence — that the batch was manufactured and tested in accordance with the marketing authorisation, that the manufacturing site was under GMP control, that deviations have been investigated and resolved, and that traceability from raw materials to finished product is complete.
QP Certification vs QP Declaration — Understanding the Distinction
European distributors sourcing from India need to understand two distinct QP instruments. QP certification guarantees that each batch of medicinal products is manufactured and tested according to stringent regulations, ensuring the products’ safety, quality, and efficacy. QP declaration confirms that APIs comply with GMP and are fit for use. If you are importing finished medicinal products, QP certification applies to every batch. If you are importing active pharmaceutical ingredients for further manufacturing, QP declaration is the relevant instrument.
The distinction matters because the regulatory pathway — and the documentation requirements — differ between finished products and APIs. Attempting to import finished products under the framework that applies to APIs, or vice versa, will result in regulatory non-compliance that your national authority will identify.
Batch Quarantine Before Release
A manufacturing relationship has to be contracted between the importer of the medicinal product and the contracted manufacturer to cover the storage area of the batch originating in a third country that has not yet been released by the importer’s qualified person. For this reason, it has to be stored in a quarantined warehouse. This quarantine requirement means your EU import facility must have adequate, GMP-compliant quarantine storage. Batches received from India cannot enter the supply chain until QP certification is complete. Your logistics and storage planning must account for the time and space this requires.
EU GMP Compliance — What It Means for Indian Manufacturers
Any manufacturer of medicines intended for the EU market must comply with EU good manufacturing practice (GMP) no matter where in the world they are located. For Indian pharmaceutical manufacturers, this means their facilities must meet EU GMP standards — not just Indian GMP standards, not just WHO GMP standards — before their products can legally enter the EU market.
EU GMP is codified in EudraLex Volume 4, which consists of four parts and twenty-one annexes. The parts most relevant to Indian manufacturers exporting to Europe are Part I (basic requirements for finished medicinal products) and Part II (GMP requirements for active substances, equivalent to ICH Q7). Annex 21, which specifically governs the importation of medicinal products, establishes additional requirements for MIA holders and their Indian manufacturing partners.
GMP Annex 21 and Its Implications
GMP Annex 21 establishes GMP requirements for MIA holders importing medicinal products from outside the EU/EEA. Under Annex 21, the EU importer is responsible for ensuring that the Indian manufacturer complies with EU GMP — not just for assuming it. The certifying QP must compare analytical results from the import test site with the certificate of analysis from the third-country manufacturer and ensure an ongoing stability program is in place, even if testing occurs in a third country, as long as the QP has access to stability data.
The implication for European distributors is significant. Your QP is not simply reviewing paperwork. They are taking personal regulatory responsibility for a verification process that spans your import facility and the Indian manufacturer’s site. The written agreements between your organisation and the Indian manufacturer must reflect this — they must assign responsibilities clearly, give the QP access to all relevant batch documentation, and establish what happens in the event of a deviation or non-compliance.
How to Verify an Indian Pharmaceutical Manufacturer’s EU GMP Status
Verifying the EU GMP status of an Indian pharmaceutical manufacturer is a specific, structured process — not a general due diligence exercise. The primary verification tool is the EudraGMDP database.
The EudraGMDP Database
After inspecting a manufacturing site, EU competent authorities issue a GMP certificate or a non-compliance statement, which is entered in the EudraGMDP database. The EudraGMDP public database is accessible without registration and allows you to search for an Indian manufacturer by name, site address, or product category. A valid, current GMP certificate in EudraGMDP confirms that an EU or EEA national competent authority has inspected that specific manufacturing site and found it compliant.
Search results in EudraGMDP will show you the certificate number, the issuing national competent authority, the date of the most recent inspection, and the product categories covered by the certificate. Certificates are typically valid for three years from the date of the last inspection — though this period can be extended or reduced by the issuing authority. A certificate that is more than three years old without a more recent inspection should be treated with caution and verified directly with the issuing authority before relying on it.
Non-Compliance Statements — What to Look For
EudraGMDP also contains non-compliance statements — issued in cases where critical or major deficiencies are identified during an inspection, or in the case of a refusal to be inspected. Before engaging with any Indian pharmaceutical manufacturer for EU supply, search their site name in EudraGMDP and check for non-compliance statements alongside GMP certificates. A non-compliance statement against a specific site means that site cannot currently supply compliant product to the EU market until the deficiency is resolved and a re-inspection confirms correction.
This check takes minutes and is a non-negotiable step in any responsible supplier qualification process. An Indian manufacturer who does not appear in EudraGMDP at all — no certificate, no non-compliance statement — has not been inspected by an EU authority and cannot be considered EU GMP compliant for your purposes.
Marketing Authorisation Verification
Separate from GMP compliance, the specific product you intend to import must have a valid EU marketing authorisation (MA) before it can be sold or supplied. Medicines must have a valid EU marketing authorisation or be supplied via a marketing authorisation holder. The EMA medicines database covers centrally authorised products. National authorisations are held by the competent authority of the relevant member state. Verify the MA status of the specific product and the specific authorised manufacturer before any supply agreement is finalised.
Documentation Requirements for Indian Pharma Imports into the EU
The documentation requirements for importing pharmaceutical products from India to the EU are extensive and must be complete before QP certification can proceed. Every batch imported from India requires a certificate of analysis from the Indian manufacturer, a batch manufacturing record summary, documentation of all deviations and their resolution, stability data relevant to the shelf life claimed, and full traceability from raw material receipt through to finished product release.
Beyond batch-specific documentation, your written agreements must be in place before any importation begins. A written agreement should be signed between the parties engaged in manufacturing and importation activities and the marketing authorisation holder and should set out the respective responsibilities of the MAH, the importer, the QC testing laboratory, the QP certification site, and the third country manufacturer. This agreement is not optional — it is a regulatory requirement that inspectors will look for during an MIA inspection.
Understanding how a structured export operation manages documentation discipline and pre-shipment verification — across every stage from order through to delivery — is something the NexaCrest How We Work framework addresses directly. While pharmaceutical exports operate under a substantially more complex regulatory framework than other Indian export categories, the foundational principles — specification lock, documented chain of control, and accountability at every stage — apply across all serious export operations.
Frequently Asked Questions
What is a Manufacturing and Import Authorisation (MIA) and do I need one to import Indian pharmaceuticals into the EU?
Yes. Any organisation importing medicinal products from outside the EEA — including India — into the EU must hold a Manufacturing and Import Authorisation (MIA) issued by the national competent authority of the EU member state where the import operation is based. The MIA classifies the importer as a manufacturer under EU law and requires the organisation to comply with EU GMP, maintain a pharmaceutical quality system, employ a Qualified Person, and operate GMP-compliant quarantine storage. Without an MIA, importing medicinal products from India into the EU is not legally permissible. Organisations that do not wish to obtain their own MIA can contract with an established EU MIA holder who provides QP services under their own authorisation.
How do I check whether an Indian pharmaceutical manufacturer is EU GMP compliant?
Search the EudraGMDP public database — maintained by the European Medicines Agency — using the manufacturer’s site name or address. A valid, current GMP certificate in EudraGMDP confirms that an EU or EEA national competent authority has inspected that specific site and found it compliant. Also check for non-compliance statements, which indicate that critical or major deficiencies were found during inspection. A site with no entry in EudraGMDP has not been EU-inspected and cannot be considered EU GMP compliant. GMP certificates are typically valid for three years from the date of the last inspection.
What is the role of the Qualified Person (QP) in pharmaceutical imports from India?
The Qualified Person is the EU-regulated individual legally responsible for certifying each imported batch of medicinal products before it is released onto the EU market. No batch imported from India can be sold or supplied in the EU without QP certification. The QP reviews batch manufacturing records, analytical results, deviation investigations, and stability data, then issues a formal certification that the batch complies with the EU marketing authorisation and was manufactured under GMP control. The QP takes personal regulatory responsibility for this certification. Every EU MIA holder must have access to a nominated QP, either employed directly or contracted from an authorised third party.
If you are building an Indian sourcing operation across categories and want to understand how a structured, accountable export process is governed from the supplier side, the NexaCrest How We Work page explains the framework we apply to every order — including pre-shipment verification, documentation control, and post-delivery accountability. For pharmaceutical imports specifically, we always recommend working with a specialist EU regulatory consultant alongside any export partner, given the complexity of the MIA and QP requirements involved.